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Abstract 23 
 24 
The in vitro effects of 18 dinuclear-thiolato bridged arene ruthenium complexes, (1 mono-, 4 25 
di- and 13-tri-thiolato compounds), originally designed as anti-cancer agents, were studied in 26 
the apicomplexan parasite Toxoplasma gondii grown in human foreskin fibroblast host cells 27 
(HFF).  Some tri-thiolato compounds exhibited anti-parasitic efficacy at 250 nM and below. 28 
Among those, complex 1 and complex 2 inhibited T. gondii proliferation with IC50 values of 29 
34 and 62 nM, respectively, and they did not affect HFF at dosages of 200 µM or above, 30 
resulting in selectivity indices of > 23’000. The IC50 values of complex 9 were 1.2 nM for T. 31 
gondii and above 5 µM for HFF. TEM detected ultrastructural alterations in the matrix of the 32 
parasite mitochondria at the early stages of treatment, followed by more pronounced 33 
destruction of tachyzoites. However, all three compounds applied at 250 nM for 15 days were 34 
not parasiticidal.  By affinity chromatography using complex 9 coupled to epoxy-activated 35 
sepharose followed by mass spectrometry, T. gondii translation elongation factor-1 alpha and 36 
two ribosomal proteins, RPS18, and RPL27 were identified as potential binding proteins. In 37 
conclusion, organometallic ruthenium complexes exhibit promising activities against 38 
Toxoplasma, and potential mechanisms of action of these compounds as well as their 39 
prospective applications for the treatment of toxoplasmosis are discussed.  40 
 41 
  42 
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INTRODUCTION 43 
Organometallic compounds, especially platinum complexes, are widely applied as anti-cancer 44 
chemotherapeutics (1). However, due to their drawbacks (i.e. severe side effects, insurgence 45 
of tumor resistance, etc.), a variety of complexes of other transition metals such as copper, 46 
gold or ruthenium have been investigated as potential alternative anti-cancer drug candidates 47 
(2-10). Among the different metal complexes studied, arene ruthenium complexes showed 48 
very promising anti-cancer properties with 50% inhibitory concentration (IC50) values in the 49 
low micromolar range, and certain selectivity for tumor cells over non-tumorigenic cells (11-50 
13). One such compound, namely RAPTA-C, is currently in pre-clinical evaluation (14). 51 
Recently, some of us have shown that thiolato-bridged dinuclear arene ruthenium complexes, 52 
in particular trithiolato dinuclear complexes of the type [(6-p-MeC6H4Pr
i)2Ru2(µ2-SR)3]
+ and 53 
[(6-p-MeC6H4Pr
i)2Ru2(µ2-SR
1)(µ2-SR
2)2]
+, were among the most cytotoxic ruthenium 54 
complexes reported so far, with nanomolar IC50 values against both A2780 human ovarian 55 
cancer cells and their cisplatin-resistant mutant variant A2780cisR (15-21). Interestingly, in 56 
vivo studies on one of these compounds, namely [(6-p-MeC6H4Pr
i)2Ru2(µ2-SC6H4-p-Bu
t)3]
+ 57 
(diruthenium-1) demonstrated a significant increase in survival of treated mice (22).  58 
 Arene ruthenium complexes also showed to be effective against bacteria (23), against 59 
protozoan parasites including the two closely related apicomplexans Neospora caninum  and 60 
Toxoplasma gondii(24) and against helminths such as Schistosoma mansoni (25, 26) and 61 
Echinococcus multilocularis (27). Interestingly, some ruthenium-clotrimazole (ctz) complexes 62 
displayed high in vitro activity against Leishmania major and Trypanosoma cruzi and low 63 
toxicity when assessed in normal mammalian cells (28). In addition to ruthenium, other 64 
organometallic complexes have also been reported to display interesting anti-parasitic or/and 65 
anti-infective activities (29-42). For instance, one manganese(I) tricarbonyl complex, 66 
[Mn(CO)3(bpy
R,R)(ctz)]PF6,, showed submicromolar activity against Staphylococcus aureus 67 
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and S. epidermidis with minimum inhibitory concentrations (MICs) of 0.625 μM. Moreover, 68 
the related complex [Mn(CO)3(bpy
R,R)(ktz)]PF6,  (ktz = ketoconazole) was active against 69 
Trypanosoma brucei with an IC50 value of 0.7 μM, while the IC50 value in mammalian cells 70 
was more than 10 times higher (43).  71 
Among the different above-mentioned pathogens, T. gondii is the most widespread parasite 72 
worldwide, and infects approximately one third of the human population (44). In general, T. 73 
gondii infestation remains without clinical symptoms in immune competent individuals, and 74 
no treatment is required. However, Toxoplasma infection has been linked to neuropsychiatric 75 
disease. Importantly, upon immunosuppression, or primary infection during pregnancy, T. 76 
gondii can cause toxoplasmosis, a life-threatening disease affecting both humans but also 77 
food and farm animals, which can lead to severe pathology including fetal malformation and 78 
abortion. Current treatment options for toxoplasmosis include macrolide antibiotics and 79 
sulfonamides (45), which inhibit protein biosynthesis and intermediary metabolism in the 80 
apicoplast, a prokaryote-like organelle that is unique to apicomplexans (46). However, these 81 
treatments are often characterized by adverse side effects, and do not eliminate the parasite, 82 
thus do not act in a parasiticidal manner. It is therefore of high interest to investigate whether 83 
dinuclear thiolato-bridged arene ruthenium complexes exhibit selective toxicity and 84 
parasiticidal activity against T. gondii. Moreover, compounds with good efficacy against T. 85 
gondii have good chances of being active against related apicomplexan parasites of high 86 
medical and veterinary medical interest such as the coccidians Cryptosporidium and Eimeria, 87 
and the closely related Neospora caninum. 88 
 89 
MATERIALS AND METHODS 90 
Chemicals and synthesis of ruthenium complexes. All reagents were commercially 91 
available and were used as received. The complexes assessed in this study are shown in Fig. 92 
 o
n
 August 9, 2017 by Universitaetsbibliothek Bern
http://aac.asm
.org/
D
ow
nloaded from
 
1. The symmetrical trithiolato complexes 1-7 were synthesized following a slightly modified 93 
published protocol (17). The dinuclear complex [(6-p-MeC6H4Pr
i)Ru2(-Cl)Cl2] was first 94 
dissolved and heated in refluxing technical grade ethanol, and a solution of 6 equivalents of 95 
the corresponding thiol SR in 5 mL technical grade ethanol EtOH was added dropwise (R = 96 
4-C6H4CH3: 1; 4-C6H4Bu
t: 2; 4-C6H4OH: 3; 3,4-C6H3(OMe)2: 4; 4-mco, mco = 97 
methylcoumarinyl: 5; 3-C6H4Cl: 6; 3-C6H4NH2: 7). The resulting mixture was refluxed for 18 98 
h. After cooling to room temperature, the solvent was removed under reduced pressure. The 99 
oil obtained was purified by column chromatography on silica gel using a mixture of 100 
dichloromethane and ethanol (5:1) as the eluent. The “mixed” trithiolato complexes 8-13 were 101 
synthesized in two steps, as previously described (19, 47). First, the neutral dichlorido 102 
dithiolato intermediates [(6-p-MeC6H4Pr
i)2Ru2(µ2-SCH2-C6H4-R)2Cl2] are obtained from the 103 
reaction of the p-cymene ruthenium dichloride dimer [(6-p-MeC6H4Pr
i)Ru2(-Cl)Cl2] with 2 104 
equivalents of the respective thiol SCH2R (R = C6H5: 8; R = 4-C6H4CH3: 9; R = 4-C6H4OMe: 105 
10; R = 4-C6H4F: 11; R = 4-C6H4Cl: 12; R = 4-C6H4Br: 13 in ethanol at 0 °C, according to the 106 
published method (49). These intermediates react in refluxing ethanol during 15 h with 6 107 
equivalents of 4-Mercaptophenol 4-HS-C6H4-OH to give the corresponding mixed trithiolato 108 
complexes [(6-p-MeC6H4Pr
i)2Ru2(µ2-S-C6H4-OH)(µ2-SR)2]
+ 8-13. The dithiolato complexes 109 
14-17 and the monothiolato complex 18 were synthesized according to published methods 110 
(48, 49). The resulting complexes 1 – 18 (Fig. 1,) which were isolated as chloride or 111 
tetrafluoroborate salts are air-stable, orange to red solids and were dried in vacuum. The 112 
analytical data matched those previously reported in the literature (15, 17, 47, 48).  113 
Host cell cultivation and parasite cultures. If not stated otherwise, all tissue culture media 114 
were purchased from Gibco-BRL (Zurich, Switzerland), and biochemical reagents were from 115 
Sigma (St. Louis, MO). Human foreskin fibroblasts (HFF) and Vero cells (green monkey 116 
kidney epithelial cells) were maintained in RPMI-medium containing 10% fetal calf serum 117 
(FCS) (Gibco-BRL, Zürich, Switzerland) and antibiotics as described earlier (24). T. gondii 118 
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beta-gal (transgenic T. gondii RH expressing the beta-galactosidase gene from E. coli (50)) 119 
were maintained in Vero cells, and were isolated and separated from their host cells as 120 
described (24). 121 
In vitro assessment of drug efficacy. To study the effects of compounds against T. gondii 122 
tachyzoites in vitro, 0.5 mM stock solutions of complexes were prepared in water, sterile 123 
filtered, and stored at 4 °C. 124 
For assessment of drug efficacy against T. gondii tachyzoites, parasites were isolated (24) and 125 
assays were performed using HFF as host cells (24). In short, 5 x 103 HFF cells / well) were 126 
grown to confluence in a 96 well plate in phenol-red free culture medium at 37 °C with 5% 127 
CO2. Cultures were infected with freshly isolated T. gondii beta-gal tachyzoites beta-gal 128 
tachyzoites (1 x 103 / well) and drugs were added at the time point of infection. Initial 129 
assessments of drug efficacy were done by exposing parasite cultures to 2500 nM, 250 nM, 130 
25 nM or 2.5 nM of each compound for a period of three days, or water was added as a 131 
control. For IC50 determinations, 6 selected complexes (1-5, and 9) were added at 132 
concentrations ranging between 0 and 2000 nM. After three days at 37 °C/ 5% CO2, plates 133 
were centrifuged at 500 g, medium was removed, and cell cultures were lysed in PBS 134 
containing 0.05% Triton-X-100. After addition of 10 µL of 5 mM chlorophenol red-β-D-135 
galactopyranoside (CPRG; Roche Diagnostics, Rotkreuz, Switzerland) dissolved in PBS, the 136 
absorption shift was measured at 570 nm wavelength at various time points on a VersaMax 137 
multiplate reader (Bucher Biotec, Basel, Switzerland). The activity, measured as the release of 138 
chlorophenol red over time, was proportional to the number of live parasites down to 50 per 139 
well as determined in pilot assays. IC50 values were calculated after the logit-log-140 
transformation of relative growth and subsequent regression analysis by the corresponding 141 
software tool contained in the Excel software package (Microsoft, Seattle, WA). 142 
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In one time course experiment, 9 (100 nM) was added to HFF monolayers either 10 min prior 143 
to infection or 1 h, 5 h or 24 h post-infection with T. gondii tachyzoites. The proliferation of 144 
tachyzoites was measured after 2 days of culture as described above. 145 
For long term treatment assays, T. gondii infected HFF grown in T25 culture flasks were 146 
exposed to 250 nM of 1, 2 or 9 for a period of 15 days, after which the cultures were washed 147 
with medium and were further maintained in medium devoid of drugs. Regrowth of parasites 148 
was monitored on a daily basis by light microscopy 149 
Cytotoxicity assays on non-infected confluent HFF were performed also in 96 well plates by 150 
exposing HFF to a concentration range of 2.5 nM, 25 nM, 250 nM and 2.5 µM of each 151 
compound, and assessment of the viability by AlamarBlue assay as described (51).  152 
Transmission electron microscopy (TEM). HFF (5 x 104 per inoculum) cultured in T25 153 
tissue culture flasks for 24 h were infected with 105 T. gondii beta-gal tachyzoites, and 200 154 
nM of 1, 2 or 9 were added at 24 h post-infection. After 6, 24 or 48 h, cells were harvested 155 
using a cell scraper, and they were placed into the primary fixation solution (2.5 % 156 
glutaraldehyde in 100 mM sodium cacodylate buffer pH 7.3) for 2 h. Specimens were then 157 
washed 2 times in cacodylate buffer and were post-fixed in 2% OsO4 in cacodylate buffer for 158 
2 h, followed by washing in water, pre-staining in saturated uranyle acetate solution, and step 159 
wise dehydration in ethanol. They were then embedded in Epon 812-resin, and processed for 160 
TEM as described (24). Specimens were viewed on a Phillips 400 transmission electron 161 
microscope operating at 80 kV. 162 
Coupling of compound 9 to epoxy-activated sepharose, affinity chromatography and 163 
identification of a drug-binding protein by liquid chromatography tandem mass 164 
spectrometry (LC–MS/MS) analysis.  To prepare a complex-9-sepharose matrix, 20 mg of 165 
complex 9 were added to 0.5 mg of epoxy-sepharose suspended in 2 mL of coupling buffer 166 
(NaCO3 0.1 M, pH 9.5) followed by an incubation for two days at 37 °C on a shaker.  167 
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Furthermore, a mock epoxy-sepharose column was prepared by treatment with coupling 168 
buffer without complex 9 and blocking with ethanolamine.  Prior to the runs, both columns 169 
were combined in a tandem (mock column first, then complex-9-column) and washed with 25 170 
mL of PBS equilibrated at 20 °C.  171 
To identify potential binding proteins both from T. gondii and from the host cell, three T75-172 
flasks containing HFF monolayers were infected with 2 x 107 T. gondii tachyzoites and 173 
incubated for 3-4 days. Then, cells were harvested by scraping and pelleted (1,000 g, 10 min, 174 
4◦C). For protein extraction, frozen pellets were resuspended in 1 ml ice cold PBS containing 175 
1% Triton-X-100 and 1 mM phenyl-methyl-sulfonyl-fluoride. Suspensions were vortexed 176 
thoroughly, and centrifuged (15,200 x g), 10 min, 4◦C). Extraction of pellets was repeated 177 
twice. Supernatants were combined (5–10 mg of total protein) and subjected to affinity 178 
chromatography by loading onto the column tandem at a flow rate of 0.25 mL/min. The 179 
columns were washed with PBS until a flat baseline was detected (ca. 20 mL PBS). The 180 
columns were separated, and proteins binding to the columns were eluted with a pH shift 181 
(glycine Cl− 100 mM, pH 2.9). Fractions (3 mL) were taken before, during and after elution 182 
and precipitated overnight with 80% acetone at –20 °C. The precipitates were solubilized in 183 
30 µL of Laemmli buffer and were separated by 10% sodium dodecyl sulphate 184 
polyacrylamide gelelectrophoresis (SDS-PAGE) using a Hoefer Minigel 250 Apparatus (GE 185 
Healthcare, Little Chalfont, UK). Proteins were visualized by silver staining.  186 
For mass spectrometry analysis, colloidal Coomassie staining was applied and selected 187 
protein bands were cut out with a clean scalpel, placed into Eppendorf tubes containing 188 
ethanol/distilled water (1:4) and were stored at 4 °C. In-gel digestion/liquid chromatography 189 
tandem mass spectrometry (LC–MS/MS) analysis was performed by the Mass Spectrometry 190 
and Proteomics Facility at the Department of Clinical Research of the University of Bern 191 
(Bern, Switzerland). The sequences obtained were blasted against the UniProt database 192 
(www.uniprot.org).  193 
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 194 
RESULTS 195 
In vitro efficacy of Ru(II) complexes. The tri-thiolato complexes 1-5 and the mixed complex 196 
9 inhibited the proliferation of T. gondii with IC50 values of approximatively 500 nM or below 197 
(Table 1). The tri-thiolato complex 7 and the mixed complexes 8 and 10-13 had no 198 
measurable anti-parasitic activity or were toxic for host cells already at concentrations of 250 199 
nM or 2500 nM. The same was true for the di-thiolato complexes 14-17 and the mono-200 
thiolato complex 18. The activity of the complexes against T. gondii parallels to a certain 201 
extent the results previously found against several cancer cell lines: the IC50 values of 7 were 202 
two orders of magnitude larger than that of the other complexes (20), and the mono- and 203 
dithiolato complexes were found to be only moderately cytotoxic in vitro against cancer cell 204 
lines (IC50 values between 0.2 and 2.5 M) (48, 49).  205 
Complexes 1, 2 and 9 appeared as the most active with IC50 values of 34,  62 and 1.2  nM, 206 
respectively (see Table 1). Accordingly, host cell toxicity was investigated for these three 207 
complexes. In the presence of 1, HFF vitality was decreased to 63% of the control value at a 208 
concentration of 250µM, which was the highest concentration used in these assays. Thus, an 209 
extrapolated, but purely theoretical, IC50 value of 800 µM was calculated for 1, since the 210 
solubility limit in water-based solutions is around 500 µM. 2 did not affect vitality of HFF up 211 
to a concentration of 250 µM. 9, exhibiting the by far lowest IC50 values, had an IC50 for HFF 212 
of approximately 5 µM. Thus, all three complexes affected T. gondii tachyzoites at low 213 
nanomolar concentrations, and these effects were parasite-specific, with a high selective 214 
toxicity index: > 23,000 for 1, > 16,000 for 2, and > 5,000 for 9. Interestingly, a long-term 215 
treatment with compound 9 at 250 nM 9 over a period of up to 15 days did not eliminate all 216 
parasites, since regrowth of tachyzoites was observed 5-10 days after releasing drug pressure 217 
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for all three compounds. This indicates that these compounds acted in a parasitostatic rather 218 
than parasiticidal manner.   219 
Ultrastructural changes induced by Ru(II) complexes show that one of the primary 220 
target organelles in T. gondii tachyzoites is the mitochondrion.  To obtain more detailed 221 
information on the subcellular effects of these 3 thiolato-bridged dinuclear arene ruthenium 222 
complexes, TEM was performed on drug-treated HFF infected with T. gondii (Fig. 2, 3). Non-223 
treated parasites, exemplified in Fig. 2 were located intracellularly and were undergoing 224 
proliferation by endodyogeny within a parasitophorous vacuole (PV), surrounded by a distinct 225 
PV membrane. These parasites exhibit the typical apicomplexan structural features, including 226 
rhoptries, dense granules, micronemes, and a conoid at the anterior part. The parasite 227 
mitochondrium, filled with a structured electron dense matrix, could be readily identified in 228 
these non-treated parasites (Fig. 2C). In cultures exposed to 1, alterations within the 229 
mitochondria of T. gondii were evident already after 6 h of treatment, showing a progressive 230 
degeneration of the electron-dense intra-mitochondrial matrix (Fig. 3B-C). The interior 231 
ultrastructural organization of these mitochondria was largely distorted and only membranous 232 
residues were present in some cases. However, the outer membrane of the mitochondria was 233 
still intact, and parasites maintained their overall shape. After 48 h of treatment with 1, T. 234 
gondii tachyzoites had lost their characteristic shape, and parasites displayed a largely 235 
distorted morphology, no internal organelles were recognizable anymore, and the PV and its 236 
membrane were essentially lost. However, host cell mitochondria exhibited a normal 237 
morphology with clearly discernable cristae (Fig. 3D). Similar results were obtained in T. 238 
gondii infected cultures treated with 2 (data not shown). For treatments with 9, mitochondrial 239 
changes were not noted in T. gondii tachzyoites already after 6 h of treatment (data not 240 
shown), but similar alterations as observed during treatments with 1 became evident after 24-241 
48 h of 9 exposure (Fig. 3E, F). However, intact parasites could also be observed in cultures 242 
treated with all three complexes. Overall, this suggested that these three ruthenium complexes 243 
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induced largely similar ultrastructural changes by inducing distinct alterations in the 244 
mitochondria, and could thus act with (a) similar or identical mechanism(s) of action. 245 
Complex 9 affects extracellular parasites and interferes in adhesion, invasion or 246 
intracellular establishment, but does not act efficiently against T. gondii proliferation 247 
once parasites reside inside the host cell.  Since long-term treatment studies as well as TEM 248 
suggested that these ruthenium complexes did not act parasiticidal, we wanted to determine 249 
whether these compounds affected host cell invasion, intracellular proliferation, or both. For 250 
this, HFF monolayers were infected with T. gondii tachyzoites, and 9 (100 µM) was added 251 
either concomitantly with the infection, or after 1 h, 5 h or 24 h post infection (Fig. 4). 9 252 
efficiently inhibited tachyzoite proliferation when added at the time point of infection and 253 
also when applied at 5 h post-infection, but only partially when added 24 h post-infection. 254 
Thus 9 acted mainly during first steps of the infection process (e.g. host cell invasion and 255 
intracellular establishment), and only with limited efficacy once parasites resided inside the 256 
host cell. 257 
Complex 9 interacts with ribosomal proteins from T. gondii and from the host cell. By 258 
affinity chromatography on complex-9-epoxy-sepharose, two major bands of approximately 259 
50 kDa and 20 kDa were identified that were not present in the eluate of the mock column 260 
(Fig. 5 A).  Mass spectrometry analysis identified ribosomal proteins of host and parasite 261 
origin as major components of the 20-kDa-band (Table 1). The composition of the 50 kDa 262 
band was more heterogeneous. As quantified both via protein match score summation and via 263 
protein score – the major component of the 50 kDa-band was T. gondii elongation factor 1-264 
alpha (TgEF1-alpha; Table 1) with a unique peptide coverage of nearly 50% of the sequence 265 
(Fig. 5B). The second most abundant protein was its human homologue. Moreover, other 266 
proteins of human origin were identified in this fraction (Table 1).  267 
 268 
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DISCUSSION 269 
We here report on a series of 18 dinuclear thiophenolato-bridged arene ruthenium complexes, 270 
which exhibit highly promising in vitro activities against T. gondii tachyzoites. The 271 
organometallic complexes studied in this work have been previously described (15, 17, 47, 272 
48). Very importantly, recent studies by some of us have shown that these dinuclear arene 273 
ruthenium complexes are inert to ligand substitutions and remain stable for long period in 274 
water solutions or in organic solvents like DMSO (16, 21). These ruthenium complexes had 275 
been originally generated for the treatment of cancer cells. Cancer cells and protozoan 276 
parasites, including Toxoplasma, share several features: they both live and multiply in a host 277 
organism and do not immediately kill their hosts, they have a potentially infinite proliferative 278 
capacity, and escape in immune-compromised tissues. Cancer cells are largely resistant to 279 
apoptosis, while Toxoplasma and Neospora are known to interfere in the programmed cell 280 
death machinery of their host cell (52). Thus, we hypothesize that a potentially lucrative 281 
starting point for the discovery of novel drug candidates against T. gondii and other 282 
protozoans is to examine compounds that are being developed against cancer. 283 
Among the 18 compounds studied, the trithiolato complexes 1, 2 and 9 were highly 284 
efficacious against both parasites with IC50s ranging between 1.2 and 62 nM. In addition, 285 
these compounds exhibited a highly favorable selective toxicity index of up to 23’000. TEM 286 
demonstrated that one of the first organelles that exhibited ultrastructural alterations upon 287 
treatment with these compounds was the tachyzoite mitochondrion, which lost its interior 288 
membranous matrix and cristae already after 6-24 h. More severe distortion, including a 289 
complete breakdown of other organelles within the parasite cytoplasm and a general 290 
disintegration of the tachzoites and the parasitophorous vacuole and its membrane, was 291 
observed after 48 h.  292 
In comparison to other drugs, the in vitro results on complexes 1, 2 and 9 are encouraging. 293 
Pyrimethamine, sulfadiazine and atovaquone, compounds currently clinically used against 294 
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toxoplasmosis, inhibited T. gondii beta-gal with IC50 values of 1 mM, 80 µM and 19-50 nM, 295 
respectively (50). The calcium dependent protein kinase inhibitor BKI-1294, highly active 296 
against T. gondii and N. caninum infections in mice, inhibited T. gondii and N. caninum beta-297 
gal proliferation under identical conditions with an IC50 of 137 and 40 nM, respectively (53). 298 
Two previously identified organometallic ruthenium complexes exhibited IC50 values of 18 299 
and 41 nM (24) however, with selective toxicity indeces below 100. As can be noticed from 300 
the calculated Log P values (Table 1) and as previously observed against cancer cells (17), the 301 
efficacy of inhibition is, to some extent, correlated to the lipophilicity of the complexes. 302 
Unlike against A2780 and A2780cisR cancer cells, the most lipophilic complex, 2, is not the 303 
most potent one against T. gondii, possibly suggesting that the different chemical nature of the 304 
cell and T. gondii outer membranes could influence the uptake of dinuclear thiolato-bridged 305 
arene ruthenium complexes. 306 
While 1, 2 and 9 were highly efficacious against T. gondii and exhibited an excellent selective 307 
toxicity, we obtained evidence that these compounds did not act in a parasiticidal manner. 308 
Removal of the drugs after continuous treatments at 250 nM lasting up to 15 days did not 309 
result in complete elimination of viable tachyzoites, and re-growth of parasites was observed 310 
within 5-10 days after releasing the drug pressure. This was confirmed by TEM, where a 311 
small number of largely intact tachyzoites were still found after 48 h of continuous in vitro 312 
treatment. Similar results were previously reported for dicationic arylimidamides (54) and 313 
ruthenium phosphite complexes in T. gondii (24), and for buparvaquone, the BKI-1294 as 314 
well as for artemisinin derivatives in the closely related N. caninum (55-57). In some of these 315 
reports, rapid adaptation of T. gondii and N. caninum tachyzoites to increased concentrations 316 
of drugs within a few days was documented (54, 56). This outstanding adaptive ability 317 
represents a major obstacle for the development of efficacious drugs against these parasites. 318 
Nevertheless, the lack of parasiticidal activity in vitro still allows for excellent in vivo 319 
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efficacy, as documented for the BKI-1294 in pregnant murine infection models for N. 320 
caninum (55, 57). 321 
All three compounds had a profound impact on the ultrastructure of the parasite mitochondria, 322 
which lost their characteristic electron dense matrix and cristae upon 6-24 h after initiation of 323 
drug treatments. After 48 h, this impacted on the entire tachyzoites, leading in most cases to 324 
severe alterations and death. Of note, mitochondria are also targeted by other drugs currently 325 
used against apicomplexans, such as atovaquone, buparvaquone and decoquinate, which have 326 
been shown to impair cytochrome b/c1 complex in Toxoplasma, Plasmodium and Theileria 327 
parasites (58-61).  328 
The mitochondrion represents an attractive drug target. The disruption of mitochondria has 329 
been recently investigated as a potential novel chemotherapeutic mechanism for cancer 330 
treatment, because it circumvents upstream apoptotic pathways that may be mutated or 331 
lacking in cancer cells (62). Moreover, cancer cells have higher mitochondrial membrane 332 
potentials, rendering them more susceptible to mitochondrial perturbations than non-333 
immortalized cells (63). On the basis of these factors, numerous mitochondria-targeting 334 
agents have been developed in order to disrupt the mitochondrial membrane potential and to 335 
further permeabilize the mitochondrial outer membrane. Some ruthenium(II) complexes can 336 
induce mitochondria–mediated apoptosis in cancer cells (64-67). However, while in 337 
mammalian cells the mitochondrion represents the main ATP-generating organelle that allows 338 
complete oxidation of carbohydrates, lipids and amino acids via the tricarboxylic acid (TCA) 339 
cycle and the electron transport chain, the situation in apicomplexans appears slightly 340 
different. Apicomplexans have a single tubular mitochondrial network that also hosts part of 341 
the heme biosynthesis, iron-sulfur cluster assembly, and lipoic acid salvage, and the 342 
mitochondrion participates in the synthesis of many metabolic intermediates including 343 
pyrimidines (68)  344 
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How exactly the mitochondrion is targeted by our ruthenium complexes is not known. 345 
Affinity chromatography using extracts from T. gondii-infected HFF lead to the identification 346 
of TgEF1-alpha as well as its human homologue as major complex-3-binding partners. This is 347 
not surprising since EF1-alpha is expressed in all eukaryotic cells and is highly conserved 348 
(69). In eukaryotic cells, EF1-alpha promotes the GTP-dependent transfer of aminoacylated 349 
tRNA to the ribosome A site, hence represents an essential component of protein synthesis. In 350 
addition, other activities have been attributed to EF1-alpha in different eukaryotes, which are 351 
associated with vital cellular functions such as cell growth, motility, protein metabolism, 352 
signal transduction, DNA replication/repair protein networks and apoptosis (70-72). In 353 
Trypanosoma brucei and T. gondii, EF1-alpha mediates the specificity of mitochondrial t-354 
RNA import (73, 74) and disruption of this process could lead to the observed mitochondrial 355 
alterations.  356 
In another apicomplexan parasite, Cryptosporidium parvum, CpEF1-alpha was shown to 357 
localize to the apical region of C. parvum sporozoites, and antibodies directed against 358 
CpTEF1-apha inhibited host cell invasion (75).  The same was shown for T. gondii (76) Our 359 
study also showed that complex 9 had a profound efficacy when applied at the early stages of 360 
host cell infection, namely either during, or 1-5 h after, exposure of T. gondii tachyzoites to 361 
host cells, but more limited efficacy was noted when added 24 h after infection. This would 362 
be consistent with a mode of action that is relevant for invasion or early host cell 363 
establishment. In addition, vaccination of mice with recombinant TgEF1-1alpha and a DNA 364 
vaccine coding for TgEF1-alpha lead to significantly prolonged survival times in T. gondii 365 
infected mice (76, 77) underlining the importance of TgEF1-alpha for the infection process.  366 
As outlined in Table 1, other ribosomal proteins both of host and parasite origin, and various 367 
other host proteins, were found to bind to 9 as well. This may explain the low, but still 368 
detectable, host cell toxicity of 9. 369 
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In conclusion, we have identified three promising dinuclear thiolato-bridged arene ruthenium 370 
complexes with promising and highly specific anti-parasitic activity, as assessed against T. 371 
gondii. These complexes induce severe mitochondrial alterations within 6-24 h of drug 372 
treatment, efficiently inhibit proliferation, but do not act in a parasiticical manner. One of 373 
these complexes, compound 9, interacts with TgTEF1-alpha and other parasite and host 374 
ribosomal proteins. Further studies will focus on the interactions of 9 and other promising 375 
ruthenium complexes with putative apicomplexan drug targets, and on the use of these drugs 376 
in vivo.  377 
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Figure legends 665 
FIG. 1. Structures of complexes 1-18 used in this study. Note that compounds 1, 2 and 9 were 666 
further characterized. 667 
 668 
FIG. 2. Ultrastructure of T. gondii tachyzoites grown in HFF. A is a low magnification view 669 
of infected HFF, the boxed area is shown at a higher magnification in B. Tachyzoites 670 
proliferate within a parasitiophorous vacuole, surrounded by a parasitophorous vacuole 671 
membrane. Nuc = nucleus, dg = dense granules, mic = micronemes, rop = rhoptries, mito = 672 
mitochondrion. The boxed area in B shows the mitochondrial matrix and is enlarged in C. Bar 673 
in A = 1.8 µm, B = 0.3 µm, C = 0.1 µm 674 
 675 
FIG. 3.  Ultrastructure of T. gondii tachyzoites grown in HFF and treated with ruthernium 676 
compounds 1 and 9. Treatments were carried out using 200 nM of compounds 1 (A-D) or 9 677 
(E, F). A is a low magnification view of parasites treated with compound 1for 6 h, the boxed 678 
areas are enlarged in B and C. D shows parasites exposed to compound 1 for 48 h. E and F 679 
show parasites exposed to compound 9 during 24 h. Note the distinct alterations in the 680 
mitochondria (mito) in B, C and E, and the still intact host cell mitochondria (h-mito) in D¨. 681 
The boxed area in F is enlarged in E. Bar in A, F = 1 µm, B, C, E = 0.4 µm, D = 0.8 µm,  682 
 683 
FIG. 4. Compound 9 inhibits T. gondii tachyzoite proliferation only when applied early 684 
during infection. HFF monolayers grown in 96 well plates were treated with compound 9   685 
(100 nM) either 10 min prior to infection or 1 h, 5 h or 24 h post-infection with T. gondii 686 
tachyzoites. The proliferation of tachyzoites was measured after 2 days of culture by beta-687 
galactosidase assay as described in materials and methods 688 
 689 
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FIG. 5. Identification of complex 9-binding proteins. A, SDS-PAGE and silver staining of 690 
tandem (mock- and compound 9-sepharose) affinity chromatography of a protein extract 691 
prepared from T. gondii infected HFF. Soluble extract and non-binding fraction (flow-692 
through) are shown on the left, followed by wash and eluate fractions of the mock columns 693 
and the complex 9-sepharose column. The two arrows point to the two bands of 50 kda and 694 
20 kDa, which were cut out and analyzed by LC-MS. B shows the amino acid sequence of the 695 
50 kDa band identified as TgEF1-alpha, the peptide sequences identified by LC-MS are 696 
underlined.  697 
  698 
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Tables 699 
 700 
 701 
Table 1. The efficacies of dinuclear thiolate-bridged arene ruthenium complexes against T. 702 
gondii beta-galactosidase expressing tachyzoites, host cell (HFF) cytotoxicity, and respective 703 
physicochemical data. Chloride salts of the corresponding thiols of the complexes [1-6] were 704 
used for all experiments. For the determination of efficacies, confluent HFF monolayers 705 
grown in a 96-well plate were treated with the complexes at various concentrations, and were 706 
infected with T. gondii beta-gal tachyzoites (10
3
 per well). After 3 days, beta-galactosidase 707 
activity or host cell viability were determined, IC50 values were calculated as described, and 708 
are presented with 95% confidence intervals. The LogP values correspond to the values that 709 
were calculated for the thiols RSH groups [ref17].  nd = not done 710 
 711 
 712 
Complex
 T. gondii beta-gal 
IC50 (nM) 
HFF 
IC50 (µM) 
LogP 
(RSH) 
1  34 ± 4 
 
800 2.98 ± 0.28 
2  62 ± 10 >1000 4.21 ± 0.29 
3 130 ± 20 nd 2.38 ± 0.32 
4 120 ± 20 nd 2.83 ± 0.42 
5 540 ± 60 nd 1.68 ± 0.29 
9 1.2 ± 0.5 5‘129 nd 
 713 
 714 
 715 
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Table 2. Results of mass spectrometry analysis of the two major bands shown in Fig. 5. AC, UniProt accession number; ID, UniProt identifier; 717 
PMSS, protein match score summation. 718 
Band AC ID PMSS Protein 
Score 
 unique 
peptides 
Coverage 
(%) 
Protein 
Mass (Da) 
Description 
20 kDa P46783 RS10_HUMAN 79 147 5 32.7 18898 40S ribosomal protein S10  
 P30050 RL12_HUMAN 72 161 5 43.0 17819 60S ribosomal protein L12  
 S8FA78 S8FA78_TOXGO 46 86 3 25.5 17821 Ribosomal protein RPL12 
 V4YUP9 V4YUP9_TOXGO 30 69 3 21.8 16331 Ribosomal protein RPL27 
 P62269 RS18_HUMAN 29 67 3 19.1 17719 40S ribosomal protein S18  
 S8EUB1 S8EUB1_TOXGO 26 61 3 21.8 17723 Ribosomal protein RPS18 
 P61254 RL26_HUMAN 25 55 3 16.6 17258 60S ribosomal protein L26  
 P62851 RS25_HUMAN 24 35 2 13.6 13742 40S ribosomal protein S25  
 Q5SGD8 Q5SGD8_TOXGO 18 37 2 11.1 19983 Tgd057 
50 kDa S8GV85 S8GV85_TOXGO 323 518 17 47.5 49006 Elongation factor 1-alpha 
 P68104 EF1A1_HUMAN 143 196 8 22.9 50141 Elongation factor 1-alpha 1  
 O14773-2 TPP1_HUMAN 71 120 5 27.2 34464 Isoform 2 of Tripeptidyl-peptidase 1  
 P63261 ACTG_HUMAN 36 77 4 14.7 41793 Actin, cytoplasmic 2  
 P06576 ATPB_HUMAN 32 61 3 8.3 56560 ATP synthase subunit beta, 
mitochondrial 
 P22234 PUR6_HUMAN 26 47 2 6.1 47079 Multifunctional protein ADE2 
 P16989-2 YBOX3_HUMAN 22 42 2 8.3 31947 Isoform 2 of Y-box-binding protein 3  
 O75821 EIF3G_HUMAN 18 32 2 5.0 35611 Eukaryotic translation initiation factor 3 
subunit G  
 Q9Y6N5 SQRD_HUMAN 17 31 2 6.2 49961 Sulfide:quinone oxidoreductase, 
mitochondrial 
 719 
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FIG. 1. Structures of complexes 1-18 used in this study. Not that compounds 1, 2 and 9 
were further characterized. 
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FIG. 2. Ultrastructure of T. gondii tachyzoites grown in HFF. A is a low magnification view of infected 
HFF, the boxed area is shown at a higher magnification in B. Tachyzoites proliferate within a 
parasitiophorous vacuole, surrounded by a parasitophorous vacuole membrane. Nuc = nucleus, dg = 
dense granules, mic = micronemes, rop = rhoptries, mito = mitochondrion. The boxed area in B shows 
the mitochondrial matrix and is enlarged in C. Bar in A = 1.8 µm, B = 0.3 µm, C = 0.1 µm 
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FIG. 3.  Ultrastructure of T. gondii tachyzoites grown in HFF and treated with ruthernium 
compounds 1 and 9. Treatments were carried out using 200 nM of compounds 1 (A-D) or 9 (E, F). A is 
a low magnification view of parasites treated with compound 1for 6 h, the boxed areas are enlarged 
in B and C. D shows parasites exposed to compound 1 for 48 h. E and F show parasites exposed to 
compound 9 during 24 h. Note the distinct alterations in the mitochondria (mito) in B, C and E, and 
the still intact host cell mitochondria (h-mito) in D¨. The boxed area in F is enlarged in E. Bar in A, F = 
1 µm, B, C, E = 0.4 µm, D = 0.8 µm,  
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FIG. 4. Compound 9 inhibits T. gondii tachyzoite proliferation only when 
applied early during infection. HFF monolayers grown in 96 well plates were 
treated with compound 9   (100 nM) either 10 min prior to infection or 1 h, 5 h 
or 24 h post-infection with T. gondii tachyzoites. The proliferation of tachyzoites 
was measured after 2 days of culture by beta-galactosidase assay as described 
in materials and methods 
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MGKEKTHINLVVIGHVDSGKSTTTGHLIYKLGGIDKRTIEKFEKESSEMGKGSFKYAWVL 
DKLKAERERGITIDIALWQFETPKYHYTVIDAPGHRDFIKNMITGTSQADVALLVVPAEA 
GGFEGAFSKEGQTREHALLAFTLGVKQMIVGINKMDSCNYSEDRFNEIQKEVAMYLKKVG 
YNPEKVPFVAISGFVGDNMVEKSTNMSWYKGKTLVEALDTMEAPKRPSDKPLRLPLQDVY 
KIGGIGTVPVGRVETGILKAGMVLTFAPVGLTTECKSVEMHHEVMEQAVPGDNVGFNVKN 
VSVKELKRGYVASDSKNDPAKGCATFLAQVIVLNHPGEIKNGYSPVIDCHTAHIACKFAE 
IKTKMDKRSGKTLEEAPKCIKSGDAAMVNMEPSKPMVVEAFTDYPPLGRFAVRDMKQTVA 
VGVIKSVEKKEPGAGSKVTKSAVKAAKK 
FIG. 5. Identification of complex 9-binding proteins. A, SDS-PAGE and silver staining of tandem 
(mock- and compound 9-sepharose) affinity chromatography of a protein extract prepared from T. 
gondii infected HFF. Soluble extract and non-binding fraction (flow-through) are shown on the left, 
followed by wash and eluate fractions of the mock columns and the complex 9-sepharose column. 
The two arrows point to the two bands of 50 kd and 20 kDa, which were cut out and analyzed by 
LC-MS. B shows the peptide sequence of TgEF1-alpha, the peptide sequences identified by LC-MS 
are underlined.  
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